Samir Undevia
Section of Hematology / Oncology
Clinical Associate of Medicine
Referring Physician Access Line: 1-877-DOM-2730

Training

DegreeYearInstitutionArea
BS1992Cornell UniversityElectrical Engineering
MD1997New York UniversityMedicine
Residency2000The University of ChicagoInternal Medicine
Fellowship2004The University of ChicagoHematology Oncology

Academic Interests

Dr. Undevia is involved in clinical research in the areas of genitourinary oncology ( kidney, bladder and prostate), bone and soft tissue sarcoma, and new drug development.


Clinical Interests

Genitourinary cancers (kidney, bladder, prostate, testis); bone and soft tissue sarcomas; investigational drug therapy


Representative Publications

  1. Undevia SD, Vogelzang NJ, Mauer AM, Janisch L, Mani S, Ratain MJ. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest. New Drugs 22 449-58 (2004).
  2. Innocenti F, Undevia SD, Iyer L, Das S, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ: Genetic variants in the UDP-Glucuronosyl Transferase 1A1 gene predict the risk of severe neutropenia of irinotecan in cancer patients. J. Clin Oncol. 15 1382-8 (2004)
  3. Undevia SD, Kindler HL, Janisch L, Olson SC, Schilsky RL, Vogelzang NJ, Kimmel KA, Macek TA, Ratain MJ. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann. Oncol.2004 Nov;15(11):1705-11
  4. Innocenti F, Undevia SD, Ramirez J, Mani S, Schilsky RL, Vogelzang NJ, Prado M, Ratain MJ. A phase I trial of pharmacological modulation of irinotecan with cyclosporine A and phenobarbital. Clin. Pharmacol. Ther. 2004 Nov;76(5):490-502



More Information

For more information about Dr. Samir Undevia publications and research collaborations , please click here